Company Description
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3.
Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies.
Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Country | France |
| Founded | 1994 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 74,846 |
| CEO | Belen Garijo Lopez |
Contact Details
Address: 46, avenue de la Grande ArmEe Paris, 75017 France | |
| Phone | 33 1 53 77 40 00 |
| Website | sanofi.com |
Stock Details
| Ticker Symbol | SNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001121404 |
| CUSIP Number | 80105N105 |
| ISIN Number | US80105N1054 |
| Employer ID | 13-3529324 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Belen Garijo Lopez M.D. | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Dr. Michael Quigley Ph.D. | Chief Scientific Officer and Head of Research |
| Thomas Kudsk Larsen | Head of Investor Relations and General Medicines |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
| Fabrizio Gaudi | Head of Austrian, German and Swiss Operations |
| Erik Wallström | Head of Therapeutic Area - Neurology Development |
| Thomas Triomphe | Executive Vice President of Vaccines |
| Dr. Karin Knobe | TA Head of Rare Diseases and Rare Blood Disorders Development |
| Pablo Sardi | TA Head of Rare and Neurologic Diseases Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | N-PX | Annual Report of proxy voting record of management investment companies |
| Aug 12, 2026 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 12, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Aug 7, 2026 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 6, 2026 | 6-K | Report of foreign issuer |
| Aug 4, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Jul 30, 2026 | 6-K | Report of foreign issuer |
| Jul 30, 2026 | 6-K | Report of foreign issuer |
| Jul 28, 2026 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Jul 27, 2026 | 6-K | Report of foreign issuer |